Search results
The privileged status of orphan medicines in Germany
Pharmaceutical Technology via Yahoo Finance· 1 day agoorphan drug developers, taking advantage of the initial free pricing period and exemptions to the benefit assessment system. Under the German benefit...
Edgewise gets EU orphan drug status for muscular dystrophy drug (NASDAQ:EWTX)
Seeking Alpha· 4 days agoEdgewise Therapeutics (EWTX) has received orphan drug designation from EU regulators for sevasemten...
Edgewise's sevasemten earns EU orphan drug status By Investing.com
Investing.com· 4 days agoEdgewise Therapeutics, Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle diseases,...
Roquefort Therapeutics readies to partner as after making significant pre-clinical headway
Proactive Investors· 1 day agoRoquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said the significant preclinical progress has...
Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug
Medscape· 5 days agoThe factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal...
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Market Watch· 5 days agoFood and Drug Administration had granted ziftomenib the status as a potential treatment for relapsed/refractory NPM1-mutant acute myeloid leukemia. The FDA's designation will ...
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Morningstar· 4 days agoWINNIPEG, MB / ACCESSWIRE / April 23, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals ...
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore...
Morningstar· 2 days ago“Bezisterim” has been approved as the non-proprietary name for NE3107Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation CARSON CITY, Nev., April 25, 2024
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 5 days agoKura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company, has announced that...
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest...
WCMH Columbus· 3 days agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results ...
